Results 181 to 190 of about 22,153,604 (283)

Exercise and Motor Complications in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Levodopa remains the most effective pharmacological treatment for Parkinson's disease (PD), but long‐term use commonly leads to motor complications such as levodopa‐induced dyskinesia (LID) and motor fluctuations, significantly contributing to disability. Exercise is well‐established for improving motor and non‐motor symptoms in PD;
Priscila Nóbrega‐Sousa, Lucas H.C.C. Santos, Jane Alty, Peter Humburg, Kim Delbaere, Paulo H.S. Pelicioni   +5 more
wiley   +1 more source

Excess Food Availability Can Have Detrimental Effects on Planktotrophic Larvae: Evaluation of the Quantitative Feeding on Sea Urchin <i>Paracentrotus lividus</i> Larval Rearing. [PDF]

Aquac Nutr
Grosso L, Sousa J, Santos PM, Silva FAE, Lourenço S, Félix PM, Pombo A, Rakaj A.   +7 more
europepmc   +1 more source

Digital Handwriting Reveals Motor Impairment, Dopaminergic Response, and Progression in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Digital handwriting distinguishes PD patients from healthy controls but is rarely assessed quantitatively. Objectives To evaluate digital handwriting as an objective tool to assess motor impairment, dopaminergic response, and progression in PD.
Lola Díaz‐Feliz, Marcos Faundez‐Zanuy, Andrea Gennari, Alexia Sánchez‐Reyes, Pilar Sanz‐Cartagena, José Arbelo‐González, Miguel Ángel García‐Cabezas, Pedro García‐Ruiz   +7 more
wiley   +1 more source

Cardiomyopathy Following Olanzapine Use in an Octogenarian: A Case Report and Literature Review. [PDF]

Cureus
Abdelmoneim SS, Sole P, De la Cruz Seoane M, Palacio I, Hurtado L, Valdes P, Valle B.   +6 more
europepmc   +1 more source

Association Between Plasma Phosphorylated Tau‐217 and Cognition in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Alzheimer's disease (AD) co‐pathology contributes to dementia in PD, but its role in earlier cognitive impairment remains uncertain. Objective To determine if p‐tau217, a biomarker of early AD, is associated with cognitive impairment in PD.
Trycia Kouchache, Tevy Chan, Sophie Sun, Lang Liu, Aline Delva, Ziv Gan‐Or, Pedro Rosa‐Neto, Jean‐François Gagnon, Alain Dagher, Ronald B. Postuma, Madeleine Sharp   +10 more
wiley   +1 more source

Corrigendum to "Cultural Diversity and Kidney Replacement Therapy Outcomes in Australia" [<i>Kidney International Reports</i> Volume 11, Issue 3, March 2026, 103743]. [PDF]

Kidney Int Rep
Gois PF, Chu G, Khanal N, Sud K, Chacko B, Brotherton K, Jones S, Spicer T, Guha C, Muthuramalingam S, Mazis J, McDonald S.   +11 more
europepmc   +1 more source

DOS ENFOQUES DE PEDRO PARAMO

Revista Iberoamericana, 1989
openaire   +2 more sources

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

Movement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota, Jacy B. Parmera, Matheus Deltreggia, Pedro N. Martins, Anna Letícia M. Alves, Ananda C.M. de Falcone, Ana Rosa Santana, Maria Alice P. Falcão, Mayara A. Dias, Larissa I. Moreira, Paulo C. de Fonseca Filho, Eberval G. Figueiredo, Egberto R. Barbosa, Rubens G. Cury, Daniel C. de Andrade   +14 more
wiley   +1 more source

Intra-abdominal torsion of a cryptorchid testicle associated with teratoma in a rabbit (<i>Oryctolagus cuniculus</i>): A case report. [PDF]

Vet Anim Sci
Jacik SCC, da Silva DL, de Souza AJS, Custódio VLM, Schiavi GDS, Guimarães KOP, Souto DPBM, Gomes LS, Moncayo JR.   +8 more
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source